SCHEMBL21166259

SCHEMBL21166259

O=C(c1ccccc1)c1cc(Cl)nc(Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
CNR2 P34972 3/20 0.46
KMT2A Q03164 5/20 0.46
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
HPGD P15428 2/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 1/20 0.41
KCNMA1 Q12791 1/20 0.40
SRD5A2 P31213 1/20 0.39
CNR1 P21554 1/20 0.39
PBRM1 Q86U86 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30929761 1.00 ALDH1A1 (0.49) ALDH1A1CNR2KMT2AATMTDP1
SCHEMBL19806121 0.79 ALDH1A1 (0.47) ALDH1A1CNR2KMT2AMEN1NPC1
SCHEMBL21469785 0.77 ALDH1A1 (0.58) ALDH1A1CNR2KMT2AATMTDP1
SCHEMBL986362 0.77 KMO (0.51) ALDH1A1TDP1SMN1; SMN2LMNA
SCHEMBL24310483 0.76 ALDH1A1 (0.50) ALDH1A1CNR2KMT2AATMTDP1
SCHEMBL3655141 0.75 KMT2A (0.50) ALDH1A1CNR2KMT2AATMTDP1
Hydrochloric Acid SCHEMBL6525079 0.75 KMO (0.50) ALDH1A1TDP1SMN1; SMN2LMNA
SCHEMBL10627200 0.74 KMT2A (0.53) ALDH1A1CNR2KMT2AATMTDP1
SCHEMBL29128530 0.73 ALDH1A1 (0.58) ALDH1A1CNR2KMT2AATMTDP1
SCHEMBL5683134 0.72 LMNA (0.50) ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436667-B1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2026-01-21 EP disclosed
US-20250011300-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2025-01-09 US disclosed
EP-4436667-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2024-10-02 EP disclosed
CN-118201916-A Piperazinylsulfonylaryl compounds for the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-06-14 CN disclosed
WO-2023072794-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-05-04 WO disclosed
WO-2023072794-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-05-04 WO disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011300-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS ABL1, Q6ZSR9, NQO2 ALDH1A1 2216/4885CNR2 2030/4885KMT2A 435/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 ALDH1A1 1320/4885CNR2 949/4885KMT2A 1471/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 ALDH1A1 1320/4885CNR2 949/4885KMT2A 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.